Friedreich's Ataxia Pipeline as Novel and Extensive 10+ Therapies Likely to Enter in the Treatment Domain

DelveInsight's, "Friedreich's Ataxia Pipeline Insight, 2022," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Friedreich's Ataxia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Friedreich's Ataxia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key takeaways from the Friedreich's Ataxia Pipeline Report

• DelveInsight's Friedreich's Ataxia Pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Friedreich's Ataxia.
• The leading Friedreich's Ataxia Companies include PTC Therapeutics, Retrotope, Reata Pharmaceuticals, Minoryx Therapeutics, Larimar Therapeutics, LEXEO Therapeutics, Exicure, StrideBio, Voyager Therapeutics, Lacerta Therapeutics, and others.
• Promising Friedreich's Ataxia Pipeline therapies include TAK-831, Omaveloxolone Capsules 2.5 mg, MIN-102, MIB-626, Deferiprone, CTI-1601, Vatiquinone, and others.
• The Friedreich's Ataxia Companies and academics are working to assess challenges and seek opportunities that could influence Friedreich's Ataxia R&D. The Friedreich's Ataxia pipeline therapies under development are focused on novel approaches for Friedreich's Ataxia.

Get an overview of the Friedreich's Ataxia Pipeline Outlook Report @ https://www.delveinsight.com/report-store/friedreich-ataxia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Friedreich's Ataxia Overview

Friedreich's Ataxia (FRDA) is a genetic, progressive, neurodegenerative movement disorder, with a typical age of onset between 10 and 15 years. Initial symptoms may include unsteady posture, frequent falling, and progressive difficulty in walking due to impaired ability to coordinate voluntary movements (ataxia). Affected individuals often develop slurred speech (dysarthria), characteristic foot deformities, and an irregular curvature of the spine (scoliosis). Friedreich's Ataxia is often associated with cardiomyopathy, a disease of cardiac muscle that may lead to heart failure or irregularities in heart rhythm (cardiac arrhythmias). About a third of the people with Friedreich's Ataxia develop diabetes mellitus. The symptoms and clinical findings associated with FRDA result primarily from degenerative changes in the sensory nerve fibers at the point where they enter the spinal cord in structures known as dorsal root ganglia. This results in secondary degeneration of nerve fibers in the spinal cord which leads to a deficiency of sensory signals to the cerebellum, the part of the brain that helps to coordinate voluntary movements.

Friedreich's Ataxia Emerging Drugs

• RT 001: Retrotope
RT001 is a clinical-stage isotopically stabilized, synthetic linoleic acid (LA) discovered and developed with Retrotope's novel platform technology. This platform is designed to combat the oxidative stress and cellular degeneration that arises from lipid peroxidation (LPO). It is currently in phase III stage of development for Friedreich's ataxia and is being developed by Retrotope.

• Leriglitazone: Minoryx Therapeutics
Leriglitazone (MIN-102) is a novel, orally bioavailable and selective PPAR gamma agonist with a potential best-in-class profile indicated for CNS diseases. It is one of the several metabolites of pioglitazone and has a demonstrated sufficient brain penetration and favorable safety profile in humans, allowing PPAR gamma engagement in the CNS above the level that can be safely achieved with pioglitazone and other glitazones. It showed robust preclinical proof-of-concept in animal models of multiple diseases by modulating pathways leading to mitochondrial dysfunction, oxidative stress, neuroinflammation, demyelination and axonal degeneration. It is currently in phase II stage of development and is being developed by Minoryx Therapeutics.

Friedreich's Ataxia Therapeutics Assessment

There are approx. 10+ key companies which are developing the Friedreich's Ataxia. The companies which have their Friedreich's Ataxia drug candidates in the most advanced stage, i.e. Phase III include, Retrotope.

Friedreich's Ataxia Pipeline Report Assessment

• Friedreich's Ataxia Pipeline Product Profiles
• Friedreich's Ataxia Therapeutic Assessment
• Friedreich's Ataxia Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

For further information, refer to the detailed Friedreich's Ataxia Ongoing Clinical Trials Analysis @ https://www.delveinsight.com/sample-request/friedreich-ataxia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Friedreich's Ataxia Pipeline Report

• Coverage- Global
• Friedreich's Ataxia Companies- PTC Therapeutics, Retrotope, Reata Pharmaceuticals, Minoryx Therapeutics, Larimar Therapeutics, LEXEO Therapeutics, Exicure, StrideBio, Voyager Therapeutics, Lacerta Therapeutics, and others.
• Friedreich's Ataxia Pipeline therapies- TAK-831, Omaveloxolone Capsules 2.5 mg, MIN-102, MIB-626, Deferiprone, CTI-1601, Vatiquinone, and others.
• Friedreich's Ataxia Emerging Drugs, Unmet Needs, Analyst Views

Table of Content
1. Introduction
2. Friedreich's Ataxia Executive Summary
3. Friedreich's Ataxia: Overview
4. Friedreich's Ataxia Pipeline Therapeutics
5. Friedreich's Ataxia Therapeutic Assessment
6. Friedreich's Ataxia- DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Friedreich's Ataxia Collaboration Deals
9. Late Stage Products (Phase III)
10. RT 001: Retrotope
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. Leriglitazone: Minoryx Therapeutics
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. CTI-1601: Larimar Therapeutics
17. Drug profiles in the detailed report…..
18. Preclinical and Discovery Stage Products
19. LX-2006: LEXEO Therapeutics
20. Drug profiles in the detailed report…..
21. Inactive Products
22. Friedreich's Ataxia Key Companies
23. Friedreich's Ataxia Key Products
24. Friedreich's Ataxia- Unmet Needs
25. Friedreich's Ataxia- Market Drivers and Barriers
26. Friedreich's Ataxia- Future Perspectives and Conclusion
27. Friedreich's Ataxia Analyst Views
28. Friedreich's Ataxia Key Companies
29. Appendix

Key Questions

Current Scenario and Friedreich's Ataxia Emerging Therapies:

• How many companies are developing Friedreich's Ataxia drugs?
• How many Friedreich's Ataxia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Friedreich's Ataxia?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Friedreich's Ataxia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Friedreich's Ataxia and their status?
• What are the key designations that have been granted to the emerging drugs?

For further information on Friedreich's Ataxia Pipeline therapeutics, reach out to Friedreich's Ataxia Treatment Landscape @ https://www.delveinsight.com/sample-request/friedreich-ataxia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09193216187
Address: 304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.